Melatonin treatment normalizes plasma pro‐inflammatory cytokines and nitrosative/oxidative stress in patients suffering from Duchenne muscular dystrophy
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Duchenne muscular dystrophy (DMD), a lethal disorder characterized by dystrophin absence, courses with chronic inflammation, sarcolemmal damage, and skeletal muscle degeneration. Among the multiple pathogenic mechanisms proposed for DMD, oxidative stress and inflammation are directly involved in the dystrophic process. Unfortunately, there is no current treatment for DMD, and the inflammatory process is an important target for therapies. Based on the antioxidant and anti‐inflammatory properties of melatonin, we investigated whether melatonin treatment may reduce the dystrophic process. Ten DMD patients aged 12.8 ± 0.98 yr, were treated with melatonin (60 mg at 21:00 hr plus 10 mg at 09:00 hr), and plasma levels of lipid peroxidation (LPO), nitrites (NOx), interleukin (IL)‐1β, IL‐2, IL‐6, tumor necrosis factor‐α, interferon‐γ, and plasma markers of muscle injury, were determined at 3, 6 and 9 months of treatment. Healthy age‐ and sex‐matched subjects were used as controls. The results show a significant increase in LPO, NOx, and cytokine levels in plasma of DMD patients compared with controls. Melatonin administration reduced these values to control levels at 3 months of treatment, decreasing further 9 months later. In parallel, melatonin also reduced plasma levels of creatine kinase (CK; 50%), lactate dehydrogenase (28%), aspartate aminotransferase (28%), alanine aminotransferase (20%), and myoglobin (13%). These findings strongly support the conclusion that melatonin administration significantly reduced the hyperoxidative and inflammatory process in DMD patients, reducing the muscle degenerative process.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Activators and target genes of Rel/NF-κB transcription factors
Pahl, H. L. (1999) · Oncogene · doi:10.1038/sj.onc.1203239 · Cited by 3,727
Green, L. C., Ruiz de Luzuriaga, K., Wagner, D. A., Rand, W., Istfan, N., Young, V. R., & Tannenbaum, S. R. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.12.7764 · Cited by 665
A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice
Wehling, M., Spencer, M. J., & Tidball, J. G. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.200105110 · Cited by 530 · cited 1×
“This explains why l-arginine given to mdx mice may have beneficial effects: l-arginine acts as a substrate for nNOS yielding cytoprotective NO• levels, but impedes iNOS expression blocking NF-kB [54].”
BackgroundVillalta, S. A., Nguyen, H. X., Deng, B., Gotoh, T., & Tidball, J. G. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn376 · Cited by 512 · cited 2×
“Besides INF-c and IL-2, IL-6 levels were also elevated in our study prior to melatonin treatment, which was related to the dystrophy progress in DMD patients [19, 51].”
BackgroundMason, M. G., Nicholls, P., Wilson, M. T., & Cooper, C. E. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506562103 · Cited by 233 · cited 1×
“But, after induction of iNOS, the high amounts of NO• are responsible for cytotoxic effects, mainly due to the inhibition of mitochondria respiration and the nitrosation/nitrosylation effects on proteins [52, 53].”
BackgroundEscames, G., Acuña-Castroviejo, D., López, L. C., Tan, D.-X., Maldonado, M. D., Sánchez-Hidalgo, M., León, J., & Reiter, R. J. (2006) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.58.9.0001 · Cited by 118
Self-citation
Cited by
Galano, A., Tan, D. X., & Reiter, R. J. (2011) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2011.00916.x · Cited by 1,146
Melatonin: Buffering the Immune System
Carrillo-Vico, A., Lardone, P., Álvarez-Sánchez, N., Rodríguez-Rodríguez, A., & Guerrero, J. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14048638 · Cited by 740
Extrapineal melatonin: analysis of its subcellular distribution and daily fluctuations
Venegas, C., García, J. A., Escames, G., Ortiz, F., López, A., Doerrier, C., García‐Corzo, L., López, L. C., Reiter, R. J., & Acuña‐Castroviejo, D. (2012) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2011.00931.x · Cited by 577
Self-citationMelatonin as a mitochondria-targeted antioxidant: one of evolution's best ideas
Reiter, R. J., Rosales-Corral, S., Tan, D. X., Jou, M. J., Galano, A., & Xu, B. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2609-7 · Cited by 558
Dietary Sources and Bioactivities of Melatonin
Meng, X., Li, Y., Li, S., Zhou, Y., Gan, R.-Y., Xu, D.-P., & Li, H.-B. (2017) · Nutrients · doi:10.3390/nu9040367 · Cited by 362
Metadata
- Authors
- Chahbouni, M., Escames, G., Venegas, C., Sevilla, B., García, J. A., López, L. C., Muñoz‐Hoyos, A., Molina‐Carballo, A., & Acuña‐Castroviejo, D.
- Venue
- Journal of Pineal Research
- Publisher
- Wiley
- Published
- 2010-03-08
- Volume
- 48
- Issue
- 3
- Pages
- 282-289
- ISSN
- 0742-3098 (ISSN-L)
- 1600-079X
- OpenAlex
- W2050585388
- Cited by
- 151
- References
- 6
- FWCI
- 6.50
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Melatonin treatment normalizes plasma pro‐inflammatory cytokines and nitrosative/oxidative stress in patients suffering from Duchenne muscular dystrophy. https://app.cochat.ai/papers/10.1111/j.1600-079x.2010.00752.x
- The paper
- Chahbouni, M., Escames, G., Venegas, C., Sevilla, B., García, J. A., López, L. C., Muñoz‐Hoyos, A., Molina‐Carballo, A., & Acuña‐Castroviejo, D. (2010). Melatonin treatment normalizes plasma pro‐inflammatory cytokines and nitrosative/oxidative stress in patients suffering from Duchenne muscular dystrophy. Journal of Pineal Research. https://doi.org/10.1111/j.1600-079x.2010.00752.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.